Abstract
5064 The GeT regimen - gemcitabine (dFdC) + treosulfan (TREO) - has been found to be active in metatastic melanoma and refractory epithelial ovarian carcinoma (EOC). However, the q3w regimen with dFdC at 1250mg/m2 day 1+8 and TREO at 5000 mg/m2 day 1 was associated with myelosuppression negatively influencing dose intensity and, consecutively, progression-free survival (PFS). Since maintaining cellular accumulation appears to be crucial for long-lasting responses, this phase II trial in platinum- and taxane refractory Mullerian carcinomas (MC) was set up using a modified q2w GeT protocol with dFdC at 450 mg/m2 (3 h infusion) day 1 and oral TREO at 1000 mg/m2 day 1–4. A total of 25 patients (pts) were included (EOC: n=24; papillary-serous endometrial carcinoma: n=1). Patients had failed a median of 2 prior Ctx (1: n=9; 2: n=6; 3: n=5; 4: n=2; 5: n=2) including platinum and paclitaxel in all, anthracyclines in 9 and topotecan or dFdC in either 4 pts. A total of 145 cycles were given with a median of 6 (range: 2–10). All pts had measurable or evaluable disease according to the RECIST and Rustin criteria, repectively. All treatments were evaluable for both toxicity and response. Anemia which was never therapy-limiting was frequent but exceeded NCI-CTC grade 2 in only 8/145 cycles (6%). Leukopenia > grade 2 was not observed. In one patient, interval prolongation was necessary due to febrile urinary tract infection. In another patient, treatment was terminated due to non-lethal pulmonary embolism. Other toxicities did not exceed NCI-CTC grade 1 nor did any other patient require hospitalization due to therapy-related toxicities. A total of 9 CR and 4 PR were recorded accounting for an objective response rate of 52%; 6 pts achieved SD and 6 pts progressed on GeT. The median progression-free survival was 29 weeks. Until now, only 5 pts have died, so that the median overall survival is not yet reached. Facing the intensive pre-treatment of the pts studied, it can be concluded that the modified GeT protocol is well tolerated and exhibits a promising clinical activity in MC refractory to both platinum and taxanes that warrants further exploration in large-scaled clinical trials. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration L.a.n.c.e. Inc.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call